Biotechnology

Avaí Bio's new deal for its Insulinova therapy brings a mysterious, world-class partner to the table, signaling a major step toward a functional cure for diabetes.

The life sciences giant beat expectations with a 60% earnings jump, raising its 2026 forecast. Key drivers include the Masimo deal and a new acquisition plan.

Berlin-based OMEICOS gets a major FDA boost, advancing its novel PMD drug OMT-28 directly to a pivotal Phase 3 trial. A deep dive into the science.

Arcturus Therapeutics heads to the Canaccord Growth Conference to spotlight its advanced mRNA platform, shifting focus from COVID vaccines to rare diseases.

With key hires from Vivodyne and Ferring, Conceivable Life Sciences isn't just staffing up; it's signaling a full-scale assault on the IVF market.

New research reveals how IntraBio's AQNEURSA recalibrates cellular function, a novel mechanism that could revolutionize treatment for a wide range of diseases.

A Rwandan-owned company reports promising results for a long-acting TB drug. It could transform treatment, but it also signals a shift in global health innovation.

A new study validates Actinogen's cortisol-inhibiting drug for depression, creating a strategic tailwind for its primary Alzheimer's program due in November.

Dogwood Therapeutics hits a critical trial milestone for its non-opioid pain drug, signaling a potential breakthrough for millions of cancer survivors.

Kolon TissueGene's revolutionary knee therapy, once a beacon of hope, fails a pivotal Phase 3 trial, raising questions about its future and the broader field.

IntelliGenome's revolutionary CRISPR-TB diagnostic arrives in South Africa via a key partnership, offering a new, blood-based tool to tackle the TB crisis.

With FDA Fast Track and a key ESMO presentation, Nouscom is de-risking its pioneering cancer interception therapy, NOUS-209, for Lynch Syndrome.

Kamada's new plasma supply agreement is more than just revenue; it's a bold validation of its vertical integration strategy in a competitive global market.

With promising new data, Nuvation Bio is launching a bold, multi-front clinical strategy for its brain cancer drug. Is this the move that will outmaneuver competitors?

With a new CEO famed for a $2.4B exit and a reverse merger in play, Mentari Therapeutics isn't just developing drugs; it's building a powerhouse.

A struggling medtech firm and an AI drug developer merge. It's not just a deal; it's a new blueprint for innovation, funded by high-risk capital.

Kibow Biotech's AANP award for its kidney health probiotics isn't just a win for the company; it's a major nod to the growing role of the gut-kidney axis.

VST Capital’s Atlas Healthcare Fund is posting staggering returns by ignoring financial models and reading lab reports. Is this the future of investing?

Arch Biopartners is fast-tracking a novel therapy for diabetic kidney disease, targeting IL-32 to address a massive unmet medical need for millions globally.

Neurizon Therapeutics completes enrollment for its NUZ-001 ALS trial at record speed, accelerating the timeline for potential new treatment data to 2027.